5
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      The dural angioleiomyoma harbors frequent GJA4 mutation and a distinct DNA methylation profile

      research-article
      1 , 2 , , 1 , 3 , 4 , 5 , 6 , 7 , 5 , 6 , 2 , 8 , 2 , 8 , 8 , 9 , 10 , 10 , 11 , 12 , 12 , 13 , 14 , 3 , 15 , 16 , 16 , 5 , 6 , 1 , 4 , 4 , 1 , 2 , 1 , 17 , 1 , 18 , 19 , 18 , 19 , 1 , 2 , the RENOCLIP-LOC
      Acta Neuropathologica Communications
      BioMed Central
      Dural angioleiomyoma, GJA4, DNA methylation profile

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The International Society for the Study of Vascular Anomalies (ISSVA) has defined four vascular lesions in the central nervous system (CNS): arteriovenous malformations, cavernous angiomas (also known as cerebral cavernous malformations), venous malformations, and telangiectasias. From a retrospective central radiological and histopathological review of 202 CNS vascular lesions, we identified three cases of unclassified vascular lesions. Interestingly, they shared the same radiological and histopathological features evoking the cavernous subtype of angioleiomyomas described in the soft tissue. We grouped them together with four additional similar cases from our clinicopathological network and performed combined molecular analyses. In addition, cases were compared with a cohort of 5 soft tissue angioleiomyomas. Three out 6 CNS lesions presented the same p.Gly41Cys GJA4 mutation recently reported in hepatic hemangiomas and cutaneous venous malformations and found in 4/5 soft tissue angioleiomyomas of our cohort with available data. Most DNA methylation profiles were not classifiable using the CNS brain tumor (version 12.5), and sarcoma (version 12.2) classifiers. However, using unsupervised t-SNE analysis and hierarchical clustering analysis, 5 of the 6 lesions grouped together and formed a distinct epigenetic group, separated from the clusters of soft tissue angioleiomyomas, other vascular tumors, inflammatory myofibroblastic tumors and meningiomas. Our extensive literature review identified several cases similar to these lesions, with a wide variety of denominations. Based on radiological and histomolecular findings, we suggest the new terminology of “dural angioleiomyomas” (DALM) to designate these lesions characterized by a distinct DNA methylation pattern and frequent GJA4 mutations.

          Related collections

          Most cited references88

          • Record: found
          • Abstract: found
          • Article: not found

          The 2021 WHO Classification of Tumors of the Central Nervous System: a summary

          The fifth edition of the WHO Classification of Tumors of the Central Nervous System (CNS), published in 2021, is the sixth version of the international standard for the classification of brain and spinal cord tumors. Building on the 2016 updated fourth edition and the work of the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy, the 2021 fifth edition introduces major changes that advance the role of molecular diagnostics in CNS tumor classification. At the same time, it remains wedded to other established approaches to tumor diagnosis such as histology and immunohistochemistry. In doing so, the fifth edition establishes some different approaches to both CNS tumor nomenclature and grading and it emphasizes the importance of integrated diagnoses and layered reports. New tumor types and subtypes are introduced, some based on novel diagnostic technologies such as DNA methylome profiling. The present review summarizes the major general changes in the 2021 fifth edition classification and the specific changes in each taxonomic category. It is hoped that this summary provides an overview to facilitate more in-depth exploration of the entire fifth edition of the WHO Classification of Tumors of the Central Nervous System.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found

            DNA methylation-based classification of central nervous system tumours

            Summary Accurate pathological diagnosis is crucial for optimal management of cancer patients. For the ~100 known central nervous system (CNS) tumour entities, standardization of the diagnostic process has been shown to be particularly challenging - with substantial inter-observer variability in the histopathological diagnosis of many tumour types. We herein present the development of a comprehensive approach for DNA methylation-based CNS tumour classification across all entities and age groups, and demonstrate its application in a routine diagnostic setting. We show that availability of this method may have substantial impact on diagnostic precision compared with standard methods, resulting in a change of diagnosis in up to 12% of prospective cases. For broader accessibility we have designed a free online classifier tool (www.molecularneuropathology.org) requiring no additional onsite data processing. Our results provide a blueprint for the generation of machine learning-based tumour classifiers across other cancer entities, with the potential to fundamentally transform tumour pathology.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              The 2020 WHO Classification of Soft Tissue Tumours: news and perspectives

              Mesenchymal tumours represent one of the most challenging field of diagnostic pathology and refinement of classification schemes plays a key role in improving the quality of pathologic diagnosis and, as a consequence, of therapeutic options. The recent publication of the new WHO classification of Soft Tissue Tumours and Bone represents a major step toward improved standardization of diagnosis. Importantly, the 2020 WHO classification has been opened to expert clinicians that have further contributed to underline the key value of pathologic diagnosis as a rationale for proper treatment. Several relevant advances have been introduced. In the attempt to improve the prediction of clinical behaviour of solitary fibrous tumour, a risk assessment scheme has been implemented. NTRK-rearranged soft tissue tumours are now listed as an “emerging entity” also in consideration of the recent therapeutic developments in terms of NTRK inhibition. This decision has been source of a passionate debate regarding the definition of “tumour entity” as well as the consequences of a “pathology agnostic” approach to precision oncology. In consideration of their distinct clinicopathologic features, undifferentiated round cell sarcomas are now kept separate from Ewing sarcoma and subclassified, according to the underlying gene rearrangements, into three main subgroups (CIC, BCLR and not ETS fused sarcomas) Importantly, In order to avoid potential confusion, tumour entities such as gastrointestinal stroma tumours are addressed homogenously across the different WHO fascicles. Pathologic diagnosis represents the integration of morphologic, immunohistochemical and molecular characteristics and is a key element of clinical decision making. The WHO classification is as a key instrument to promote multidisciplinarity, stimulating pathologists, geneticists and clinicians to join efforts aimed to translate novel pathologic findings into more effective treatments.
                Bookmark

                Author and article information

                Contributors
                a.tauziede-espariat@ghu-paris.fr
                Journal
                Acta Neuropathol Commun
                Acta Neuropathol Commun
                Acta Neuropathologica Communications
                BioMed Central (London )
                2051-5960
                31 May 2022
                31 May 2022
                2022
                : 10
                : 81
                Affiliations
                [1 ]GRID grid.414435.3, ISNI 0000 0001 2200 9055, Department of Neuropathology, , Sainte-Anne Hospital, ; 1, Rue Cabanis, 75014 Paris, France
                [2 ]GRID grid.512035.0, Inserm, UMR 1266, IMA-Brain, , Institut de Psychiatrie et Neurosciences de Paris, ; Paris, France
                [3 ]GRID grid.460789.4, ISNI 0000 0004 4910 6535, Department of Radiology, Gustave Roussy, Univ. Paris-Sud, , Université Paris-Saclay, ; 94805 Villejuif, France
                [4 ]GRID grid.50550.35, ISNI 0000 0001 2175 4109, Department of Pathology, Lariboisière Hospital, , APHP, ; 75475 Paris, France
                [5 ]GRID grid.460789.4, ISNI 0000 0004 4910 6535, U981, Molecular Predictors and New Targets in Oncology, Team Genomics and Oncogenesis of Pediatric Brain Tumors, INSERM, Gustave Roussy, , Université Paris-Saclay, ; 94805 Villejuif, France
                [6 ]GRID grid.460789.4, ISNI 0000 0004 4910 6535, Département de Cancérologie de l’Enfant et de l’Adolescent, Gustave Roussy, , Université Paris-Saclay, ; 94805 Villejuif, France
                [7 ]GRID grid.50550.35, ISNI 0000 0001 2175 4109, Department of Neurovascular Molecular Genetics, Saint-Louis Hospital, , APHP, ; 75010 Paris, France
                [8 ]GRID grid.414435.3, ISNI 0000 0001 2200 9055, Department of Neurosurgery, , Sainte-Anne Hospital, ; 75014 Paris, France
                [9 ]GRID grid.412116.1, ISNI 0000 0001 2292 1474, Department of Neurosurgery, , Henri Mondor Hospital, ; 94000 Créteil, France
                [10 ]GRID grid.508487.6, ISNI 0000 0004 7885 7602, Department of Pediatric Neurosurgery, Necker Hospital, APHP, , Université Paris Descartes, Sorbonne Paris Cité, ; Paris, France
                [11 ]GRID grid.414435.3, ISNI 0000 0001 2200 9055, Department of Neuroradiology, , Sainte-Anne Hospital, ; 75014 Paris, France
                [12 ]GRID grid.410527.5, ISNI 0000 0004 1765 1301, Department of Pathology, , CHRU, ; Nancy, France
                [13 ]GRID grid.410527.5, ISNI 0000 0004 1765 1301, Department of Neurosurgery, , CHRU, ; Nancy, France
                [14 ]GRID grid.425274.2, ISNI 0000 0004 0620 5939, Service de Neuropathologie, Institut du Cerveau - Paris Brain Institute - ICM, Inserm, CNRS, Hôpitaux Universitaires La Pitié Salpêtrière - Charles Foix, , Sorbonne Université, AP-HP, ; 75013 Paris, France
                [15 ]GRID grid.508487.6, ISNI 0000 0004 7885 7602, Department of Pathology, Cochin Hospital, AP-HP Paris, , Université de Paris, ; Paris, France
                [16 ]GRID grid.508487.6, ISNI 0000 0004 7885 7602, Paediatric Radiology Department, Institut Imagine INSERM U1163 and U1299, AP-HP, Hôpital Necker Enfants Malades, , Université Paris Cité, ; 75015 Paris, France
                [17 ]GRID grid.410511.0, ISNI 0000 0001 2149 7878, Department of Pathology, Hôpital Henri-Mondor, INSERM U955, , Université Paris-Est, ; Créteil, France
                [18 ]GRID grid.5253.1, ISNI 0000 0001 0328 4908, Department of Neuropathology, Institute of Pathology, , University Hospital Heidelberg, ; Heidelberg, Germany
                [19 ]GRID grid.7497.d, ISNI 0000 0004 0492 0584, Clinical Cooperation Unit Neuropathology, German Consortium for Translational Cancer Research (DKTK), , German Cancer Research Center (DKFZ), ; Heidelberg, Germany
                Article
                1384
                10.1186/s40478-022-01384-x
                9153110
                35642047
                3906d3e7-70d7-4743-bba5-af94df9805f2
                © The Author(s) 2022

                Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

                History
                : 19 April 2022
                : 17 May 2022
                Categories
                Research
                Custom metadata
                © The Author(s) 2022

                dural angioleiomyoma,gja4,dna methylation profile
                dural angioleiomyoma, gja4, dna methylation profile

                Comments

                Comment on this article